GSK plc stock (GB0009252882): Hepatitis B trial data put London pharma group in focus

GSK plc shares on the London Stock Exchange traded lower on 05/28/2026 despite the UK group reporting positive pivotal Phase 3 data for its hepatitis B candidate bepirovirsen, which delivered double-digit functional cure rates compared with today’s standard of care.

GSK plc shares on the London Stock Exchange were modestly weaker on 05/28/2026 even as the United Kingdom-based pharmaceutical group published pivotal Phase 3 data showing that its investigational hepatitis B therapy bepirovirsen achieved functional cure rates well above current standards of care, putting the LSE-listed stock back into focus for UK and international investors, according to GSK’s press release and London market pricing data as of 05/28/2026.

In a statement released on 05/28/2026, GSK reported positive pivotal data for bepirovirsen, an antisense oligonucleotide being developed for chronic hepatitis B, with 19% of patients overall achieving a functional cure, defined as sustained loss of hepatitis B surface antigen and undetectable viral DNA after treatment and follow-up, compared with virtually no cures observed in the placebo arm, according to the company’s own trial disclosure on that date.

GSK noted that in a key secondary endpoint for patients whose baseline hepatitis B surface antigen levels were at or below 1,000 IU/ml, bepirovirsen delivered a functional cure rate of 26%, or 200 of 768 treated patients, versus zero of 393 patients in the placebo group, with a p-value below 0.001 in both pivotal trials, underscoring the statistical robustness of the results as outlined in the company’s 05/28/2026 communication.

The UK pharma company contrasted these outcomes with the less than 1% functional cure rates that are typically achieved under current chronic hepatitis B standards of care, which usually involve long-term, often lifelong, oral antiviral therapy rather than a finite treatment regimen aimed at achieving a durable functional cure, according to the same GSK materials published on 05/28/2026.

GSK said that the Phase 3 data for bepirovirsen, which targets hepatitis B virus messenger RNA, support the potential for a finite-duration treatment option that could redefine medical expectations for chronic hepatitis B, a disease that the company estimates affects nearly 300 million people globally and remains a major unmet medical need despite advances in antiviral therapy, based on information released with the 05/28/2026 data package.

In London trading on 05/28/2026, GSK shares changed hands around the mid-1,900 pence level during the session, compared with recent levels above 1,900 pence referenced in analyst commentary, leaving the UK stock down modestly on the day despite the positive clinical update, according to MarketScreener and other London Stock Exchange pricing overviews as of that date.

On Wall Street, the group’s American depositary shares continued to trade on the New York Stock Exchange under the ticker GSK, recently quoted around the low-USD 50 region on 05/28/2026, illustrating that the UK-based company remains actively listed on both its home LSE market and in the United States as a major global pharmaceuticals and vaccines player.

For German investors, GSK is also tradeable on venues such as Tradegate and Xetra in euro terms via its depositary interests, providing an additional access point outside the group’s primary London listing that mirrors movements seen on the UK home market when material news such as the bepirovirsen trial data is released.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: GSK
• Sector/industry: Pharmaceuticals and vaccines
• Headquarters/country: London, United Kingdom
• Core markets: United States, Europe, Asia-Pacific and other international markets
• Key revenue drivers: Vaccines, specialty medicines including HIV and respiratory therapies, and general medicines
• Home exchange/listing venue: London Stock Exchange (GSK); secondary listing on New York Stock Exchange (GSK)
• Trading currency: GBP on LSE; USD on NYSE

GSK plc: core business model

GSK focuses on developing and commercializing prescription medicines and vaccines, with growth driven largely by its vaccines portfolio and specialty therapies in areas such as HIV, respiratory disease and immunology.

Industry trends and competitive position

The global hepatitis B treatment market has been shifting toward regimens that aim for functional cures rather than solely suppressing viral replication, and GSK’s 05/28/2026 bepirovirsen Phase 3 data place the UK group among the drugmakers pursuing finite-duration, curative-intent approaches in a field that has long been dominated by chronic antiviral therapies.

Within the broader biopharmaceutical landscape, GSK competes with players such as Gilead Sciences and other large research-based groups that have invested in hepatitis B research, and the ability to show statistically robust cure rates in a substantial subset of patients strengthens GSK’s positioning in liver disease while complementing its established vaccine and specialty medicine franchises, according to sector reports and recent coverage that highlighted the company’s progress on Phase 3 assets and pipeline priorities.

Conclusion

The publication of positive Phase 3 data for bepirovirsen on 05/28/2026 gives GSK an additional late-stage asset in a large and underserved hepatitis B market, with double-digit functional cure rates that stand in sharp contrast to the sub-1% cure rates generally seen under current standards of care.

How regulators view these pivotal results and how quickly GSK can convert the data into filings and, potentially, commercial availability will help determine the long-term revenue contribution from bepirovirsen and its impact on the group’s broader portfolio strategy in vaccines and specialty medicines.

Investors in the United Kingdom, Germany and other markets will therefore be watching subsequent updates closely, including any regulatory milestones, commercialization plans and follow-up clinical data that could refine expectations for the asset’s role within GSK’s pipeline and competitive positioning in chronic hepatitis B.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.